We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2011 by TTY Biopharm.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: October 13, 2011
Last Update Posted: October 13, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
TTY Biopharm
To determine the overall objective response rate of pegylated liposomal doxorubicin (Lipo-Dox)combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.

Condition Intervention Phase
Metastatic Breast Cancer Drug: Lipo-Dox Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by TTY Biopharm:

Estimated Enrollment: 47
Study Start Date: September 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically proved breast cancer with metastatic disease

Exclusion Criteria:

  • life expectancy less than 3 months.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01451580

CGMH Recruiting
Linko, Taiwan
Contact: Wang, AN    +8862-2545-3105    monicachang@tty.com.tw   
Principal Investigator: Chang         
Sponsors and Collaborators
TTY Biopharm
Principal Investigator: Hsien-Kun Chang Chang Gung Memorial Hospital, Lin-Kou Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT01451580     History of Changes
Other Study ID Numbers: LD0411
First Submitted: October 11, 2011
First Posted: October 13, 2011
Last Update Posted: October 13, 2011
Last Verified: October 2011

Keywords provided by TTY Biopharm:
Phase II
Metastatic Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors